Home / Business and Economy / Pharma Stocks Surge on Diabetes Drug Hopes
Pharma Stocks Surge on Diabetes Drug Hopes
24 Apr
Summary
- Dr Reddy's Laboratories saw a significant jump on potential Canadian drug approval.
- The Nifty Pharma Index rose 2.4% while the benchmark Nifty declined.
- Pharma stocks are favored for their defensive qualities in uncertain markets.
On Thursday, pharmaceutical stocks demonstrated resilience against a declining market, largely propelled by Dr Reddy's Laboratories. This surge followed positive sentiment surrounding the potential approval of Semaglutide, a widely used diabetes medication, in Canada.
Dr Reddy's Laboratories recorded an impressive 9.4% increase, marking its most substantial daily gain in over six years. Other notable advancers included Piramal Pharma and Cipla. The Nifty Pharma Index consequently rose by 2.4%, while the broader Nifty index saw a marginal decrease of 0.8% on the same day.
Market analysts suggest that the upcoming target action date for Dr Reddy's generic Semaglutide filing in Canada, expected in May, may have stimulated the stock's rally. Companies involved in the Semaglutide value chain, such as OneSource Specialty Pharma and Shaily Engineering Plastics, also experienced significant gains.
This shift towards pharmaceutical shares is attributed to their defensive positioning, offering stability in an environment of economic unpredictability. Fund managers are reportedly rebalancing portfolios towards these safer assets, especially given the fragile geopolitical climate.
